证券代码：833230 证券简称：欧康医药 公告编号：2024-091 成都欧康医药股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 28 日 2.会议召开地点：公司 B 区技术中心办公楼三楼第二会议室 3.会议召开方式：现场结合通讯方式 4.发出董事会会议通知的时间和方式：2024 年 10 月 22 日以书面方式发出 5.会议主持人：董事长赵卓君 6.会议列席人员：全体监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规 章等规范性文件，符合《公司法》、《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 独立董事胥兴军、张霜因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2024 年第三季度报告>的议案》 1.议案内容： 根 ...

Financial Performance - Operating revenue for the first nine months of 2024 reached CNY 223,826,491.38, a 31.83% increase from CNY 169,781,662.69 in the same period of 2023[4] - Net profit attributable to shareholders for the first nine months of 2024 was CNY 19,526,091.61, up 54.23% from CNY 12,660,076.62 year-on-year[4] - Basic earnings per share increased by 52.94% to CNY 0.26 for the first nine months of 2024, compared to CNY 0.17 in the same period of 2023[4] - In Q3 2024, operating revenue was CNY 91,517,316.49, representing a 59.01% increase from CNY 57,555,852.54 in Q3 2023[4] - Net profit attributable to shareholders in Q3 2024 surged by 135.22% to CNY 5,678,588.17, compared to CNY 2,414,185.81 in Q3 2023[4] - Total operating revenue for the first nine months of 2024 reached ¥223,826,491.38, a significant increase of 31.8% compared to ¥169,781,662.69 in the same period of 2023[21] - Total operating costs for the same period were ¥201,402,456.95, up 26.6% from ¥159,181,541.57 in 2023[21] - Net profit for the first nine months of 2024 reached ¥21,167,587.14, a significant increase from ¥12,764,111.63 in the same period of 2023, representing a growth of approximately 66.5%[24] - Operating profit for the first nine months of 2024 was ¥25,593,540.83, up from ¥12,889,004.88 in 2023, reflecting an increase of approximately 98.5%[23] Cash Flow - Cash flow from operating activities showed a significant decline, with a net outflow of CNY 12,729,953.33, down 173.88% from a net inflow of CNY 17,230,872.40 in the previous year[4] - The company’s cash and cash equivalents decreased by 63.18% to CNY 18,967,926.25 due to the utilization of raised funds for projects and payments for raw materials[5] - Cash inflow from sales of goods and services was CNY 234,019,482.97, up from CNY 197,947,413.73 in the same period of 2023, reflecting a growth of about 18.2%[25] - The cash outflow for purchasing goods and services was CNY 232,097,518.50, compared to CNY 165,063,324.53 in the previous year, indicating an increase of approximately 40.5%[25] - Cash inflow from investment activities totaled CNY 266,774,071.59, up from CNY 200,206,644.85 in the previous year, marking an increase of about 33.2%[26] - The net cash flow from investment activities was -CNY 13,023,463.82, an improvement from -CNY 39,798,265.70 in the same period of 2023[26] - Cash inflow from financing activities was CNY 28,560,809.00, a decrease from CNY 35,360,785.00 in the previous year, reflecting a decline of approximately 19.9%[26] - The net cash flow from financing activities was -CNY 7,174,678.16, compared to -CNY 23,257,853.78 in the same period of 2023, indicating a reduced outflow[26] Assets and Liabilities - Total assets increased by 8.78% to CNY 492,896,698.71 as of September 30, 2024, compared to CNY 453,093,129.65 at the end of 2023[4] - The company's current assets decreased from 294,402,629.11 yuan at the end of 2023 to 234,863,474.45 yuan, a decline of about 20.2%[15] - The company's total liabilities increased from 59,718,298.80 yuan to 83,114,169.44 yuan, reflecting a rise of about 39.2%[17] - The company’s non-current liabilities totaled 5,229,200.38 yuan, up from 3,874,085.13 yuan, indicating an increase of approximately 35%[17] - The company’s equity attributable to shareholders rose from 393,209,412.92 yuan to 409,173,051.30 yuan, an increase of approximately 4.1%[17] - The accounts receivable increased from 63,263,660.23 yuan to 79,838,351.47 yuan, representing a growth of about 26.3%[15] - The company's inventory increased slightly from 73,931,694.95 yuan to 74,678,189.19 yuan, a growth of about 1%[15] Expenses - Sales expenses surged by 157.66% to ¥2,928,687.34, resulting from an increase in sales personnel and participation in more domestic and international exhibitions[6] - Management expenses grew by 75.81% to ¥10,447,827.51, primarily due to salary increases for management and additional personnel in the U.S. subsidiary[6] - Research and development expenses for the first nine months of 2024 were ¥9,025,240.80, a decrease of 16.0% compared to ¥10,729,104.02 in the same period of 2023[21] - The company reported a credit impairment loss of ¥1,140,300.91 for the first nine months of 2024, compared to a gain of ¥212,535.09 in 2023[23] - The company incurred asset impairment losses of ¥2,002,103.30 in the first nine months of 2024, compared to ¥478,285.04 in 2023, indicating a significant increase in losses[23] Future Plans - The company plans to apply for a credit line of up to 120 million yuan from banks, with actual control and major shareholders providing guarantees as needed[13] - The company plans to expand its market presence and invest in new product development to drive future growth[21]

证券代码：833230 证券简称：欧康医药 公告编号：2024-092 成都欧康医药股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：监事会主席顾兵 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规章 等规范性文件，符合《公司法》、《公司章程》的有关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 根据《公司法》、《证券法》、《北京证券交易所上市公司持续监管指引第 2 号——季度报告》的规定，公司组织编制了《2024 年三季度报告》。 具体内容详见公司于 2024 年 10 月 30 日在北京证券交易所信息披露平台 1.会议召开时间：2024 年 10 月 28 日 2.会议召开地点：公司 B 区技术中心办公楼三楼第二会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：202 ...

证券代码：833230 证券简称：欧康医药 公告编号：2024-092 成都欧康医药股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规章 等规范性文件，符合《公司法》、《公司章程》的有关规定。 5.会议主持人：监事会主席顾兵 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于审议<2024 年第三季度报告>的议案》 1.议案内容： 根据《公司法》、《证券法》、《北京证券交易所上市公司持续监管指引第 2 号——季度报告》的规定，公司组织编制了《2024 年三季度报告》。 具体内容详见公司于 2024 年 10 月 30 日在北京证券交易所信息披露平台 （一）会议召开情况 （www.bse.cn）披露的《2024 年三季度报告》（公告编号：2024-090）。 2.议案表决结 ...

证券代码：833230 证券简称：欧康医药 公告编号：2024-091 成都欧康医药股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 28 日 2.会议召开地点：公司 B 区技术中心办公楼三楼第二会议室 3.会议召开方式：现场结合通讯方式 4.发出董事会会议通知的时间和方式：2024 年 10 月 22 日以书面方式发出 5.会议主持人：董事长赵卓君 会议应出席董事 9 人，出席和授权出席董事 9 人。 独立董事胥兴军、张霜因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于审议<2024 年第三季度报告>的议案》 1.议案内容： 根据《公司法》、《证券法》、《北京证券交易所上市公司持续监管指引第 2 号 ——季度报告》的规定，公司组织编制了《2024 年三季度报告》。 具体内容详见公司于 2024 年 10 月 30 日在北京证券交易所信息披露平台 （ww ...

| | 公告日期 异常期间 2024-10-22 | 2024-10-22 | | | | --- | --- | --- | --- | --- | | | 成交数量 欧康医药(833230) 22535105.0 | 连续竞价 | 成交金额（万 | 42569.72 | | | （股） | | 元） | | | | 北交所股票最近3个有成交的交易日以内收盘价涨跌幅偏离值累计达到+40% 涉及事项 | | | | | | | (-40%) | | | | 买/卖 | | 营业部或交易单元名称 | 买入金额（元） | 卖出金额（元） | | 买1 | 长城证券股份有限公司西安锦业路营业部 | | 25868520.64 | 0 | | 买2 | 东莞证券股份有限公司南京分公司 | | 9745418.16 | 11996755.6 | | 买3 | 中信证券股份有限公司诸暨暨东路证券营业部 | | 6988302.25 | 57192.64 | | 买4 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | 6098496.98 | 2193503.93 | | 买5 | 机构专用 | | 58543 ...

| | 公告日期 2024-10-22 | 异常期间 | 无 | | | | --- | --- | --- | --- | --- | --- | | | 成交数量 欧康医药(833230) 连续竞价 13815937.0 （股） | | | 成交金额（万 元） | 29545.01 | | | 涉及事项 当日收盘价涨幅达到20%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 长城证券股份有限公司西安锦业路营业部 | | | 25868520.64 | 0 | | 买2 | 中信证券股份有限公司诸暨暨东路证券营业部 | | | 6988302.25 | 57192.64 | | 买3 | 机构专用 | | | 5748201.81 | 125243.4 | | 买4 | 招商证券股份有限公司深圳建安路证券营业部 | | | 5092645.08 | 202051.72 | | 买5 | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | | | 4931595.99 | 1306811.1 | | 卖1 | 广发证券 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-10- | | | | | 异常期间涨跌幅偏离值累计 | | 22 | 430489 | 佳先股份 | 33635002.0 | 98148.25 | 达到61.54% | | 2024-10- | 833230 | 欧康医药 | 22535105.0 | 42569.72 | 异常期间涨跌幅偏离值累计 | | 22 | | | | | 达到61.54% | | 2024-10- | 832149 | 利尔达 | 101682112.0 | 99444.64 | 异常期间涨跌幅偏离值累计 | | 22 | | | | | 达到61.43% | | 2024-10- | 834021 | 流金科技 | 161862752.0 | 113652.1 | 异常期间涨跌幅偏离值累计 | | 22 | | | | | 达到57.59% | | 2024-10- | 836807 | 奔朗新材 | 48740636.0 | 49375.7 | ...

证券代码：833230 证券简称:欧康医药 公告编号：2024-089 成都欧康医药股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、股票交易异常波动的具体情况 公司股票最近 2 个有成交的交易日（2024 年 10 月 21 日至 2024 年 10 月 22 日）以内收 盘价涨幅偏离值累计达到 61.54%，根据《北京证券交易所交易规则（试行）》的有关规定， 属于股票异常交易波动情形。 2、 核实对象： 公司控股股东、实际控制人及一致行动人，持股 5%以上股东，在任的董事、监事及高 级管理人员。 二、公司关注并核实的相关情况 1、 关注问题： （1）前期公告的事项是否取得重大进展或变化，前期披露的公告是否需要更正、补充； （2）是否存在可能或已经对本公司股票交易价格产生较大影响的媒体报道或市场传闻， 是否涉及热点概念事项； （3）近期公司经营情况及内外部经营环境是否或预计将要发生重大变化； （4）公司、控股股东和实际控制人是否存在关于本公司的应披露而未披露的重大事项 ...

Group 1 - The pharmaceutical sector experienced significant gains on October 22, with notable stocks such as Europharma reaching a 30% limit up, and Datang Pharmaceutical rising over 20% [1] - Europharma has achieved consecutive limit-up trading days, while Changshan Pharmaceutical has reached a new high [1] - According to Xinda Securities, the market is in a phase of oscillation and adjustment after significant fluctuations before the holiday, with companies expected to release their Q3 2024 reports in October [1] Group 2 - Short-term investment opportunities are suggested for stocks with performance likely to exceed expectations, while long-term prospects are influenced by the normalization of medical anti-corruption and centralized procurement policies [1] - High-quality innovative companies with strong R&D capabilities are expected to recover their performance first, benefiting from local government debt relief and fiscal stimulus measures in real estate [1] - Key investment themes include: 1) Core assets in innovative drugs and upstream research industry chain, such as Innovent Biologics, Kingstar Bio, BeiGene, and others [1] Group 3 - Companies benefiting from centralized procurement policies or marginal clearance include: 1) Drug packaging companies like Shandong Pharmaceutical Glass and Linuo Glass [1] - Companies in orthopedics, such as Aikang Medical and Chunli Medical, are suggested for attention due to the clearance of price impacts from centralized procurement [1] - The artificial bone market share is expected to increase following public sentiment events, with a recommendation to focus on AoJing Medical [1] Group 4 - Leading companies in consumer healthcare include: 1) Aier Eye Hospital and Tongce Medical [1] - Other notable companies in the consumer medical sector are Aibo Medical, Yuyue Medical, and Kefu Medical [1]